Literature DB >> 33112475

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

Ertao Jia1, Guangyao Yan1, Min Xiao1, Hongling Geng2, Jiaxin Wei1, Jianyong Zhang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33112475      PMCID： PMC7816240          DOI： 10.1111/dth.14470

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  9 in total

Review 1.  Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Authors:  John J O'Shea; Massimo Gadina; Robert D Schreiber
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 2.  Series introduction. JAK-STAT signaling in human disease.

Authors:  Christian W Schindler
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.

Authors:  Emma Gardette; Philippe Moguelet; Jean-David Bouaziz; Dan Lipsker; Olivier Dereure; Francois Le Pelletier; Catherine Lok; Thierry Maisonobe; Didier Bessis; Jacqueline Conard; Camille Francès; Stéphane Barete
Journal:  Acta Derm Venereol       Date:  2018-10-10       Impact factor: 4.437

4.  Livedoid vasculopathy presenting with leg ulcers.

Authors:  Ashok Kumar; Ashish Sharma; Anunay Agarwal
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

5.  Three cases of lymphocytic thrombophilic arteritis presenting with an annular eruption.

Authors:  Robert I Kelly; Edmund Wee; Chasari Tancharoen; Mei M Tam; Showan Balta; Richard A Williams
Journal:  Australas J Dermatol       Date:  2017-07-28       Impact factor: 2.875

6.  Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.

Authors:  Hui Zhang; Ryu Watanabe; Gerald J Berry; Lu Tian; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2017-12-18       Impact factor: 29.690

7.  Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

Authors:  Noha A Irani-Hakime; Farid Stephan; Raghid Kreidy; Isabelle Jureidini; Wassim Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2008-03-23       Impact factor: 2.300

8.  Targeting JAK/STAT pathway in Takayasu's arteritis.

Authors:  Patrice Cacoub; David Saadoun; Paul Régnier; Alexandre Le Joncour; Anna Maciejewski-Duval; Anne-Claire Desbois; Cloé Comarmond; Michelle Rosenzwajg; David Klatzmann
Journal:  Ann Rheum Dis       Date:  2020-03-25       Impact factor: 19.103

9.  Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  J Dermatolog Treat       Date:  2020-03-09       Impact factor: 3.359
  9 in total
  2 in total

1.  Adalimumab in Treating Refractory Livedoid Vasculopathy.

Authors:  Xiao-Wen Huang; Huan-Xin Zheng; Meng-Lei Wang; Wan-Mei He; Mei-Xin Feng; Kang Zeng; Li Li
Journal:  Vaccines (Basel)       Date:  2022-04-01

2.  Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Authors:  Maria Rosa Burg; Carolin Mitschang; Tobias Goerge; Stefan Werner Schneider
Journal:  Front Med (Lausanne)       Date:  2022-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.